Isabella Ciccone
Assistant Editor at MJH Life Sciences
Associate Editor, @neurology_live 🧠 | @TCNJ Alum 🦁 | Former @rutgersifh Research Assistant 🔬 | 📧 [email protected] | Views are my own.
Articles
-
1 week ago |
neurologylive.com | Marco Meglio |Isabella Ciccone
Huntington’s disease (HD) is a progressive, inherited neurodegenerative disorder marked by movement abnormalities, cognitive decline, and psychiatric symptoms. Caused by a CAG repeat expansion in the HTT gene, the resulting toxic buildup of mutant huntingtin protein leads to widespread neuronal damage. Despite advances in genetic testing and diagnosis, there are still no disease-modifying therapies—only symptomatic treatments that offer limited relief and do not slow progression.
-
2 weeks ago |
neurologylive.com | Isabella Ciccone
Investigators recently reported that both EN001 (ENCell), a Wharton’s jelly-derived investigational mesenchymal stem cell therapy, and insulin improved skeletal muscle strength, endurance, and remyelination in preclinical models of Charcot-Marie-Tooth disease type 1A (CMT1A).
-
2 weeks ago |
neurologylive.com | Isabella Ciccone
Investigators from an international collaboration have recently identified of thresholds for clinically meaningful differences in autonomic symptoms and overall disability in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) from the phase 3 NEURO-TTRansform study (NCT04136184).
-
2 weeks ago |
neurologylive.com | Isabella Ciccone
A newly presented real-world study reported that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with immunoglobulin (Ig) therapy had less deterioration in assistive device use than those not treated with Ig therapy, suggesting that those in the treated population experienced a reduction in disability progression.1 Researchers used US claims and electronic medical records between January 2015 and November 2021 to identify adults diagnosed with CIDP and confirmed...
-
2 weeks ago |
neurologylive.com | Isabella Ciccone |Suzanne Bertisch
CommentaryVideoMay 21, 2025Author(s):,Fact checked by:The chair of the Women’s Sleep Health Task Force at the American Academy of Sleep Medicine talked about how hormonal changes across a woman’s lifespan influence the prevalence of sleep disorders. [WATCH TIME: 4 minutes]WATCH TIME: 4 minutes"We’re really trying to put women’s sleep health on the map, knowing that sleep disorders do present differently in women, and that there are also differences in how they are recognized and treated.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 134
- Tweets
- 320
- DMs Open
- No
RT @neurology_live: #BREAKING: Last night, the @US_FDA approved Satsuma's dihydroergotamine nasal powder agent STS101, marketed as Atzumi,…
RT @neurology_live: #BREAKING: The @US_FDA has approved @JNJNews's nipocalimab, marketed as Imaavy, for the treatment of patients aged 12+…
RT @neurology_live: 🧠📘 In honor of #ParkinsonsAwareness Month, our latest Clinical Trial in Focus piece is on the phase 2 REGENERATE-PD tri…
